MiRXES

MiRXES is a pioneering biotech start-up based in Singapore, globally recognized for its innovative solutions in the healthcare sector. Established in 2014, the company was born out of a research lab at the National University of Singapore. Fueled by an insatiable desire to combat critical health issues, MiRXES leverages a proprietary technology platform to develop and market novel diagnostic solutions focused on microRNA.

At the core of MiRXES's operations is their specialization in the development of advanced microRNA-based diagnostics in Oncology, Cardiovascular and Metabolic diseases. With patented miRNA technology, the startup has successfully developed a portfolio of tests addressing disease screening, patient stratification, and treatment response prediction. Their breakthrough invention includes Gohai, the world's first microRNA in vitro diagnostic product for early-stage stomach cancer detection approved by multiple health authorities.

MiRXES's innovative approaches have positioned it as a leader in the international miRNA research community. They have an extensive network of collaborators worldwide, which includes research labs, hospitals, research institutions, and biopharmaceutical companies. With a team of dedicated professionals, MiRXES stands as a testament to Singapore's drive for medical innovation and its potential in creating influential healthcare enterprises on a global scale.

Company Details